C. W. Ritchie, A. I. Bush,A. Mackinnon, S. Macfarlane, M. Mastwyk, L. Macgregor, L. Kiers, R. Chern, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters, “Metal-Protein Attenuation with Iodochlorhydroxyquin (Clioquinol) Targeting Abeta Amyloid Deposition and Toxicity in Alzheimer Disease, A Pilot Phase 2 Clinical Trial,” Archives of Neurology, Vol. 60, No. 12, 2003, pp. 1685-1691. doi:10.1001/archneur.60.12.1685

has been cited by the following article:

• TITLE: The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies

  AUTHORS: Peter K. Panegyres, Emily R. Atkins

  KEYWORDS: Amyloid Precursor Protein, APP, Genes, Dementia, Alzheimer’s Disease

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

  ABSTRACT: Pharmacological studies reveal APP and Aβ have interactions with glutamate and calcium, cytokines, copper/zinc chelators, secretases and presenilins, nicotinic receptors, acetycholinesterase, neurotrophins, non-steroidal anti-inflame-matory drugs, monoclonal antibodies to Aβ, protease inhibitors, oestrogen, homocysteine, immediate early genes such as c-fos or c-jun and cholesterol. These functional and pharmacological observations highlight the need for greater understanding of APP and Aβ in brain function and have implications for clinical trials.